Skip to main content
xMedica

NCT07326709ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…

Phase 3770 participants sought117 sites27 countries

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 41 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.

How this score is built
  • Enrolment28/40

    770 participants (target)

  • Site count19/25

    41 sites

  • Country count12/15

    9 countries

  • Planned duration9/10

    Planned over about 50 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,104 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.

This study will have a variable double-blind treatment duration of up to 36 months. As part of the study design, not every participant will complete 36 months of treatment. The study consists of 3 periods: * Screening Period: A period of up to 42-days to assess participants eligibility * Double-blind Treatment Period: This period will have variable individual treatment duration, up to 36 months. The double-blind treatment period concludes when ≥50% patients complete Month 36. The maximum treatment duration for an individual participant is 36 months. * Safety Follow-up Period: A period consisting of one safety follow-up visit, conducted on site or by phone call, for all participants not continuing treatment in the separate open-label extension study or discontinuing early. The visit/phone call will take place 30 days after End of Study (EOS)

Conditions

  • Huntington Disease

Eligibility

Eligibility
SexAll
Ages21 Years – 70 Years
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Signed informed consents must be obtained prior to participation in the study * Ambulatory male or female participants between 21 to 70 years of age, inclusive, on the day of Informed Consent signature * Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening. * Meets all of the following criteria: * UHDRS IS score ≥90 * UHDRS TFC score = 13 * UHDRS TMS score = 7-25, inclusive * CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) / 6.49 Exclusion Criteria: * History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD * Serologic evidence for active viral hepatitis as indicated by: * positive anti-HBc IgM * positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA * positive HCV ab test confirmed by positive HCV RNA * Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result * History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker * History of familial long QT syndrome or known family history of Torsade de Pointes * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. o WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 8 months after stopping study treatment. * Pregnant or nursing (breastfeeding) women Other protocol defined inclusion/exclusion criteria may apply

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment770 participants sought

Sponsor and collaborators

  • Novartis Pharmaceuticals Sponsor

Arms and interventions

  • VotoplamEXPERIMENTAL

    Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

  • PlaceboPLACEBO_COMPARATOR

    Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

Interventions

  • Drug Placebo

    Placebo

  • Drug Votoplam (blinded)

    Votoplam (blinded) active treatment

Outcome measures

  1. Primary outcome

    Change from Baseline in cUHDRS score

    The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.

    Time frame Baseline, Month 36

  2. Secondary outcome

    Change from Baseline in UHDRS-TFC

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.

    Time frame Baseline, Month 36

  3. Secondary outcome

    Change from Baseline in UHDRS-IS

    The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Time frame Baseline, Month 36

  4. Secondary outcome

    The time to decline in TFC score by at least one or IS score by at least 10

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Time frame Baseline to end of treatment up to 36 months

  5. Secondary outcome

    Change from Baseline in UHDRS-TMS

    The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.

    Time frame Baseline, Month 36

  6. Secondary outcome

    Change from Baseline in SDMT

    The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.

    Time frame Baseline, Month 36

  7. Secondary outcome

    Change from Baseline in SWRT

    The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.

    Time frame Baseline, Month 36

  8. Secondary outcome

    Percent change from Baseline in blood mHTT protein

    The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.

    Time frame Baseline to steady state and up to 36 months in blood mHTT protein

  9. Secondary outcome

    Change from Baseline in serum NfL

    Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.

    Time frame Baseline, Month 36

  10. Secondary outcome

    Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal

    Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.

    Time frame Baseline to up to 36 months

Dates

Dates
Start dateMarch 24, 2026 (actual)
Primary completionApril 2, 2030 (estimated)
CompletionApril 30, 2030 (estimated)
First postedJanuary 8, 2026 (actual)
Last updatedSeptember 22, 2026
Results postedNot stated in the registry record
Status last verifiedSeptember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

117 sites are recruiting

Argentina

Argentina
FacilityCityState or regionStatus
Novartis Investigative SiteBuenos AiresRecruiting
Instituto Argentino de Investigación Neurológica (IADIN)CABABuenos AiresRecruiting
Centro de Investigaciones Metabólicas (CINME)CABABuenos AiresRecruiting
Novartis Investigative SiteCiudad deBuenos AiresRecruiting

Australia

Australia
FacilityCityState or regionStatus
Novartis Investigative SiteCaulfield SouthVictoriaRecruiting
Novartis Investigative SiteWestmeadNew South WalesRecruiting

Belgium

Belgium
FacilityCityState or regionStatus
Novartis Investigative SiteLeuvenVlaams BrabantRecruiting

Bulgaria

Bulgaria
FacilityCityState or regionStatus
Novartis Investigative SiteSofiaRecruiting
Novartis Investigative SiteSofiaRecruiting

Canada

Canada
FacilityCityState or regionStatus
CUSM Montreal Neurological InstituteMontrealQuebecRecruiting
Centre de recherche du CHUMMontrealQuebecRecruiting
North York General HospitalNorth YorkOntarioRecruiting

China

China
FacilityCityState or regionStatus
Novartis Investigative SiteBeijingRecruiting
Novartis Investigative SiteBeijingRecruiting
The Second Xiangya Hospital of Central South UniversityChangshaHunanRecruiting
West China Hospital of Sichuan UniChengduSichuanRecruiting
Novartis Investigative SiteFuzhouFujianRecruiting
Novartis Investigative SiteGuangzhouGuangdongRecruiting
Novartis Investigative SiteGuangzhouGuangdongRecruiting
The Second Affiliated Hosp Of Zhejiang Univ School Of MedicineHangzhouZhejiangRecruiting
Novartis Investigative SiteShanghaiRecruiting
Tongji Hos Affiliated Tongji Medical College of HuazhongWuhanHubeiRecruiting

Colombia

Colombia
FacilityCityState or regionStatus
Novartis Investigative SiteMedellínRecruiting

Czechia

Czechia
FacilityCityState or regionStatus
Novartis Investigative SiteBrnoRecruiting
Novartis Investigative SitePragueRecruiting

Denmark

Denmark
FacilityCityState or regionStatus
Novartis Investigative SiteCopenhagenRecruiting

France

France
FacilityCityState or regionStatus
Novartis Investigative SiteAngersFranceRecruiting
Novartis Investigative SiteMarseilleRecruiting
Novartis Investigative SiteMontpellierRecruiting

Germany

Germany
FacilityCityState or regionStatus
Novartis Investigative SiteAachenRecruiting
Novartis Investigative SiteBochumRecruiting
Novartis Investigative SiteMünsterRecruiting
Novartis Investigative SiteTübingenRecruiting
Novartis Investigative SiteUlmRecruiting

Hungary

Hungary
FacilityCityState or regionStatus
Novartis Investigative SiteBudapestRecruiting
Novartis Investigative SiteSzegedRecruiting

Israel

Israel
FacilityCityState or regionStatus
Tel Aviv Sourasky Med Ctr IchilovTel AvivRecruiting

Italy

Italy
FacilityCityState or regionStatus
Novartis Investigative SiteBolognaBORecruiting
Novartis Investigative SiteBresciaBSRecruiting
Novartis Investigative SiteMilanMIRecruiting
Novartis Investigative SiteMilanMIRecruiting

Japan

Japan
FacilityCityState or regionStatus
Novartis Investigative SiteBunkyo KuTokyoRecruiting
Novartis Investigative SiteKashiharaNaraRecruiting
Novartis Investigative SiteSagamiharaKanagawaRecruiting

Netherlands

Netherlands
FacilityCityState or regionStatus
Novartis Investigative SiteLeidenSouth HollandRecruiting
Novartis Investigative SiteMaastrichtLimburgRecruiting

Poland

Poland
FacilityCityState or regionStatus
Novartis Investigative SiteKrakowPOLRecruiting

Portugal

Portugal
FacilityCityState or regionStatus
Novartis Investigative SiteLisbonRecruiting
Novartis Investigative SitePortoRecruiting

Romania

Romania
FacilityCityState or regionStatus
Novartis Investigative SiteBucharestRecruiting

67 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. September 22, 2026

    Site added

    35 sites added (117 total)

    82117

  2. August 31, 2026

    Site added

    22 sites added (82 total)

    6082

  3. August 11, 2026

    Site added

    9 sites added (60 total)

    5160

  4. July 29, 2026

    Site added

    10 sites added (51 total)

    4151